[2][3][4][1][5] He developed selegiline in the 1960s and subsequently studied the drug and related agents for many decades.
[2][1] MAEs developed by Knoll and colleagues include selegiline, benzofuranylpropylaminopentane (BPAP), and phenylpropylaminopentane (PPAP), among others.
[1] Knoll is known for having extensively researched and promoted selegiline for claimed drive- and longevity-enhancing effects related to its MAE activity.
[2][4][1][5] Knoll himself began taking a low 1 mg daily dose of selegiline on January 1, 1989 at the age of 64.
[6]: 92 Knoll stated that he had become so fascinated with the possible longevity-promoting effects of selegiline he was studying that he had decided to start taking it as a self-experiment.